ASCRS Responds to Dr. Oz Regarding LASIK

The American Society of Cataract and Refractive Surgery represents more than 9,000 eye surgeons worldwide. ASCRS treats all concerns about the safety and effectiveness of LASIK very seriously. Based on substantial research and data collected over decades, ASCRS is convinced that LASIK is safe and effective, and offers a viable option for dramatically improving the quality of life for millions of qualified candidates. 

Himalayan Cataract Project/ASCRS Foundation Ethiopian Outreach Effort Featured on ABC News

The ASCRS Foundation’s collaboration with the Himalayan Cataract Project (HCP) to provide care and further cataract surgical training in Ethiopia is garnering some high-profile attention.

ABC’s World News with Diane Sawyer and Nightline featured a story on the Himalayan Cataract Project on Wednesday, October 2. Watch the story.

FDA Recall Alert: Leiter’s Compounding Pharmacy Issues National Voluntary Recall of Specific Lots of Bevacizumab and Lidocaine

Cites Lack of Assurance of Sterility Concerns Related to its Independent Testing Vendor

September 12, 2013 - The Food and Drug Administration (FDA) alerted providers and consumers this week that Leiter’s Compounding Pharmacy has issued a voluntary nationwide recall of three lots of its sterile products due to concerns of sterility assurance with Front Range Laboratories, its independent testing laboratory. 

Student Scientific Research Grant Now Available for Dry Eye and Ocular Surface Disease Studies

September 11, 2013 - A $3,000 scientific research grant to cover studies related to dry eye and ocular surface disease will be awarded by the Contact Lens Association of Ophthalmologists Education and Research Foundation (CLAO ERF) in association with the Sjögren’s Syndrome Foundation (SSF) on December 31, 2013.

Ophthalmologists, optometrists, technicians, nurses, optometry students, ophthalmology residents and fellows, and medical students supervised by a scientist associated with an academic institution in the United States are eligible.

FDA Recall Alert: Avella Specialty Pharmacy Issues Voluntary Nationwide Recall of Bevacizumab 1.25 mg/0.05 mL PF and Vancomycin PF (BSS) 1%

September 10, 2013 - Late Monday, the Food and Drug Administration (FDA) alerted providers and consumers that Avella Specialty Pharmacy is voluntarily recalling two compounded sterile medications: Bevacizumab 1.25 mg/0.05 mL PF and Vancomycin PF (BSS) 1%. The recall is a result of concerns of sterility assurance with the specialty pharmacy’s independent testing laboratory, Front Range Laboratories.